[Correspondence] Neoadjuvant chemotherapy for early breast cancer – Author's reply

We thank Petros Charalampoudis and Andreas Karakatsanis, and David Krug and Sibylle Loibl for their positive comments on our meta-analysis1 of neoadjuvant chemotherapy (NACT) versus adjuvant chemotherapy. Charalampoudis and Karakatsanis note that the incidence of local recurrence was not significantly increased in women in the neoadjuvant group with a complete clinical response compared with all women who received adjuvant chemotherapy, and hypothesise that NACT might be as safe as adjuvant chemotherapy in terms of local recurrence in complete clinical responders.

Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Paul McGale, David Dodwell, Carolyn Taylor, Richard Gray, Early Breast Cancer Trialists' Collaborative Group Tags: Correspondence Source Type: research